Tesofensine Molecular Structure: Phenyltropane SNDRI Chemistry#

Tesofensine (NS2330) is a small-molecule phenyltropane, not a peptide. It has no amino acid sequence. Its chemistry, pharmacokinetics, and structural class place it firmly within the central nervous system small-molecule drug family, distinct from the peptide GLP-1 agonists (semaglutide, tirzepatide) it is often compared with in obesity literature¹.

Identity and Basic Properties#

Structural Class: Phenyltropane#

Tesofensine is a 2-(3,4-dichlorophenyl) phenyltropane derivative. The tropane scaffold - a bicyclic [2.2.1] amine ring system - is also found in cocaine, atropine, and several CNS-active research compounds. However, tesofensine was specifically optimized at NeuroSearch in the 1990s to:

• Achieve high transporter selectivity for the serotonin, noradrenaline, and dopamine transporters (SERT, NET, DAT)
• Avoid the local-anaesthetic activity that contributes to cocaine's abuse liability
• Produce a slow onset and long duration of action incompatible with the rapid reinforcing kinetics of recreational stimulants¹

The 3,4-dichlorophenyl substituent at the tropane 2-position is the principal pharmacophore responsible for transporter binding, while N-substitution of the tropane nitrogen tunes pharmacokinetics and selectivity.

Pharmacokinetics#

Tesofensine has notably long human pharmacokinetics for a small molecule, which underpin its once-daily dosing schedule:

• Absorption: Orally bioavailable; absorbed from the gastrointestinal tract within hours
• Half-life (terminal): Approximately 220 hours (roughly 9 days)¹
• Steady state: Reached after approximately 4-6 weeks of once-daily oral dosing
• Metabolism: Hepatic, with CYP3A4 and CYP2D6 involvement reported in early pharmacology literature
• Elimination: Primarily via metabolism and biliary/renal routes

The long half-life means that effects (and side effects) persist for many days after the last dose, which has clinical implications for both withdrawal and overdose management.

Receptor / Transporter Pharmacology#

Tesofensine is a competitive inhibitor of three monoamine transporters¹:

• DAT (dopamine transporter) - blocks reuptake of dopamine into presynaptic terminals
• NET (noradrenaline transporter) - blocks reuptake of noradrenaline
• SERT (serotonin transporter) - blocks reuptake of serotonin

Reported in vitro affinity ranking generally places NET and DAT inhibition at higher potency than SERT inhibition, though exact IC50 values vary across assay systems. This "DAT-tilted SNDRI" profile is hypothesized to underlie the appetite-suppressant and weight-loss effects relative to SSRI/SNRI antidepressants, which lack potent DAT activity¹.

Stability and Formulation#

Tesofensine is supplied as an oral capsule or tablet in clinical trials. As a small molecule with a robust phenyltropane scaffold, it does not face the cold-chain, lyophilization, and reconstitution challenges of peptide drugs:

• No reconstitution required - administered orally
• No refrigeration required - room-temperature stable in standard solid dosage forms
• No injection - distinguishing it from peptide GLP-1 agonists

This pharmaceutical simplicity is a meaningful clinical advantage if efficacy and safety prove competitive with injected GLP-1/GIP peptides.

Comparison: Tesofensine vs Peptide Obesity Drugs#

References#

Related Reading#

• Tesofensine overview
• Tesofensine research studies
• Tesofensine dosing
• Semaglutide molecular structure
• Tirzepatide research guide

Footnotes#

1. Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Current Opinion in Investigational Drugs. 2009;10(10):1105-1116. PMID: 19777399. ↩ ↩² ↩³ ↩⁴ ↩⁵